Columbia University Herbert Irving Comprehensive Cancer Center | Strategic Alliance Partners

Richard Carvajal, MD, Director of Experimental Therapeutics and Director of the Melanoma Service at Columbia University Medical Center, discusses the phase III SUMIT trial, a randomized, placebo-controlled, double-blind trial of selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma.

Today, in his laboratory at Columbia University, Murty Vundavalli, PhD continues working to understand the genetic and epigenetic aspects of cervical cancer in an attempt to elucidate prognostic markers of response to treatment.

Naiyer A. Rizvi, MD, discusses the future outlook for PD-1/PD-L1 checkpoint agents in non-small cell lung cancer and the potential for immunotherapy combinations.

Owen A. O'Connor, MD, PhD, professor of Medicine and Experiment Therapies, co-program director, Lymphoid Development and Malignancy Program, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses targeting CD30 expression in patients with diffuse large B-cell lymphoma.

Owen A. O'Connor, MD, PhD, discusses the evolving use of the anti-CD30 agent brentuximab vedotin across several lymphoma types.

Dawn Hershman, MD, Associate Professor Medicine at Columbia University Medical Center, discusses the late-effects of intermittent androgen deprivation therapy (ADT) to continuous ADT in prostate cancer.

Gary Schwartz, MD, a medical oncologist and chief of the Hematology and Oncology Division at Columbia University Medical Center, discusses a randomized phase III trial investigating eribulin (Halaven) versus dacarbazine in patients with leiomyosarcoma and adipocytic sarcomas.

Joseph Jurcic, MD, professor of Clinical Medicine, director of the Hematologic Malignancies Section of the Hematology/Oncology Division, Columbia University Medical Center, discusses a phase I trial of lintuzumab and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML).

Nicole Lamanna, MD, Associate Professor of Clinical Medicine, Columbia University Medical Center, discusses incorporating novel therapies into the standard treatment paradigm for patients with chronic lymphocytic leukemia (CLL).

Mitchell Benson, MD, the Herbert and Florence Irving Professor at Columbia University Medical Center, New York-Presbyterian Hospital, discusses extensive biopsies in low-risk patients with prostate cancer.

Richard D. Carvajal, MD discusses the significance of researching, understanding, and improving outcomes for patients with rare cancers.

Richard D. Carvajal, MD, Director, Experimental Therapeutics and Melanoma Service New York-Presbyterian Hospital/ Columbia University Medical Center, discusses the challenge of using vaccines for cancer therapy.

A consensus has emerged among oncology practitioners that palliative care should not be seen as end-of-life care but is best deployed early to help patients and their caregivers manage symptoms throughout the cancer treatment trajectory.

Stephen G Emerson, MD, PhD, Clyde Wu Professor of Immunology and Medicine, director, Herbert Irving Comprehensive Cancer Center, explains the connection between stem cell mutations and leukemia.

Nicole Lamanna, MD, clinical professor of medicine, Columbia University Medical Center, discusses lymphocytosis following treatment with new, oral CLL agents.

Craig Blinderman, MD, Attending Physician in Medicine & Anesthesiology NewYork-Presbyterian Hospital/Columbia University Medical Center, Assistant Professor of Palliative Care (Medicine & Anesthesiology), Columbia University, discusses starting palliative care early in patients with metastatic disease.

Although standard induction therapy produces complete remissions in 50% to 70% of patients with acute myeloid leukemia (AML), long-term survival is seen in only 20% to 40% of patients. The prognosis for older patients is even worse, with a 5-year survival rate of 5% for patients older than 65 years.

Robert L. Fine, MD, an associate professor of Medicine at New York Presbyterian Hospital-Columbia University Medical Center, discusses a phase II study that evaluated the efficacy of neoadjuvant gemcitabine, docetaxel, and capecitabine (GTX) in patients with inoperable pancreatic adenocarcinoma

Adrienne Phillips, MD, MPH, assistant professor of clinical medicine, Columbia University Medical Center, discusses advances in the treatment of HTLV-related adult T-cell leukemia lymphoma.

Dawn L. Hershman, MD, MS, describes the HOPE study, which looked at the effect of exercise versus usual care on aromatase inhibitor-associated arthralgias (joint pain) in women with breast cancer.

Diffuse optical tomography (DOT) is a novel, fast, safe, and low-cost technique that uses near-infrared light to provide three-dimensional data on tissue vascularity without the use of radiation.

Prostate cancer is one of the most common forms of cancer in older men, with more than 200,000 new diagnoses per year.

Dawn L. Hershman, MD, MS, Associate Professor of Medicine and Epidemiology, Leader, Breast Cancer Program, Herbert Irving Comprehensive Cancer Center, Columbia University, discusses the need for adherence with longer hormonal therapy.

Dawn L. Hershman, MD, MS, discusses improving care and the use of compendia-approved oncology drugs.

OncLive is pleased to announce that the Herbert Irving Comprehensive Cancer Center has joined its Strategic Alliance Partnership program.

In September 2012 the new joint Cancer Center at Weill Cornell Medical College and NewYork-Presbyterian Hospital was established, bringing together basic, translational, and clinical researchers to operate within a vast, collaborative infrastructure.

Dr. Daniel Petrylak, from the Herbert Irving Comprehensive Cancer Center, Discusses the Future of Abiraterone Acetate

Dr. Daniel Petrylak, from Columbia University Medical Center, Discusses Chemotherapy in Prostate Cancer

The combination of lenalidomide and docetaxel for treatment of CRPC failed to produce results in the large phase III MAINSAIL trial.

Dr. Daniel Petrylak from Herbert Irving Comprehensive Cancer Center Discusses Sequencing Prostate Cancer Therapies